Celldex Therapeutics

We are dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.

[Celldex Therapeutics @Celldex]

We’re pleased to announce the closing of our $345M public offering. This will support the potential commercialization of barzolvolimab, if approved, for the treatment of CSU & the continued advancement of our novel antibody-based pipeline. Read more here. https://t.co/JfiKRwmKiP

[Celldex Therapeutics @Celldex]

We're pleased to announce the completion of enrollment in our global Phase 3 program of barzolvolimab in chronic spontaneous #urticaria. Enrollment completed 6 months ahead of guidance, driven by the significant need for better treatments in CSU. Details: https://t.co/pzh0efqE6e

[Celldex Therapeutics @Celldex]

Earlier today, @AAAAI_org shared press releases highlighting noteworthy data planned for presentation at its upcoming annual meeting, including barzolvolimab. We look forward to sharing 3 presentations at #AAAAI26 in Philadelphia, February 27 - March 2. https://t.co/dNM84TUtL8

[Celldex Therapeutics @Celldex]

As 2025 comes to an end, we're proud of the dedication & scientific rigor that drive our work forward. We gave back in our local communities & rang in the holiday season this month. We look forward to advancing our pipeline & making a meaningful impact on patients' lives in 2026.

[Celldex Therapeutics @Celldex]

We're excited to initiate our global registrational Phase 3 study of barzolvolimab in #ColdU & symptomatic dermographism, designed to establish the efficacy & safety of barzolvolimab in patients who remain symptomatic despite prior treatment. More: https://t.co/jfmYVak14B

[Celldex Therapeutics @Celldex]

Pumpkins, pies & plenty of Dunkin' - autumn is in full swing at Celldex. Recently, we voted on a delicious spiced maple miso caramel apple pie as our contest winner, celebrated Halloween with pumpkin carving & candy, & enjoyed a surprise morning sweet treat event. Check it out!🍁

[Celldex Therapeutics @Celldex]

We are thrilled to welcome Teri Lawver to our leadership team as SVP & CCO. With a notable record of success across global biopharma & medtech companies, Teri's experience will be invaluable as we prepare for the potential launch of barzolvolimab. More: https://t.co/GV4DG0Iwlb

[Celldex Therapeutics @Celldex]

We presented new Phase 2 data demonstrating sustained efficacy + a well tolerated safety profile over a 20 week treatment period for barzolvolimab in two of the most common forms of #CIndU, cold urticaria (ColdU) & symptomatic dermographism (SD). https://t.co/FpH1GKsPlq #ACAAI25

[Celldex Therapeutics @Celldex]

We're excited to announce positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets mast cell depletion via stem cell factor starvation and neutralization of the alarmin thymic stromal lymphopoietin (#TSLP). Details: https://t.co/VwIxxsWUm2

[Celldex Therapeutics @Celldex]

"I think even as a provider, there have been moments where I have not fully gauged how anxiety-provoking and emotionally challenging it can be to have chronic #urticaria."

Clinicians answer the hard questions about working with an often misunderstood community below. #UDAY2025

[Celldex Therapeutics @Celldex]

In honor of #UDAY2025, we're elevating the voices of clinicians who face the challenges of #urticaria head-on alongside their patients. Listen below as Drs. Michael Cameron, Sarina Elmariah & Daniel Soteres share insight into the exasperating symptoms #CSU and #CIndU often cause.

[Celldex Therapeutics @Celldex]

People with chronic #urticaria live with relentless itching, swelling & sleepless nights, yet many don’t see the burden. #UDAY2025 is a chance to raise awareness & amplify community voices. The Celldex team stands with those living with #CSU & #CIndU. We see you. #urticariaday

[Celldex Therapeutics @Celldex]

We are pleased to share data demonstrating barzolvolimab profoundly improves #angioedema, the swelling of the deeper dermal layers of the skin and mucous membranes, at 52 weeks in the Phase 2 clinical trial in #CSU. Learn more below & here: https://t.co/osYt181e1w #EAACI2025

[Celldex Therapeutics @Celldex]

We were pleased to present new data at #EAACI2025 demonstrating profound, sustained complete response & improved quality of life at 76 weeks—7 months post-dosing with barzolvolimab in #CSU. Find details & listen to the playback of our recent webcast here. https://t.co/gJUbYWihh8

[Celldex Therapeutics @Celldex]

Thanks to the community engagement efforts of Celldex team member Jesse Hall, we recently welcomed @BristolCC biology students & their Dean of #STEM to our Fall River branch. We appreciate opportunities to introduce students to summer internships across departments at Celldex!

[Celldex Therapeutics @Celldex]

Last week, we enjoyed a paint night organized by our Fall River Wellness Committee. We were lucky to have a warm, sunny day and enjoyed designing flower pots out by the water. It was a perfect evening to welcome spring with our teammates!🎨

[Celldex Therapeutics @Celldex]

@UMassD International Society for Pharmaceutical Engineering students recently visited our Fall River site! They experienced what a typical day at Celldex looks like for various team members. We love engaging with local schools to highlight what a career in biotech can look like.

[Celldex Therapeutics @Celldex]

Our Fall River team was excited to welcome @stonehill_info chemistry students to our office to learn about careers in #biotech. Team members guided students through a “day in the life," explaining their roles, key responsibilities & exciting aspects of working in biotech. 🔬

[Celldex Therapeutics @Celldex]

We're excited to welcome Clinical Data Manager Meghan O'Neil to Celldex! From the lab bench to clinical trials coordination, Meghan adds valuable perspective to our team. Read more about her below.

[Celldex Therapeutics @Celldex]

We are pleased to present positive data on measurements of disease control & quality of life from the Phase 2 barzolvolimab studies in patients with chronic #urticaria at #AAAAI25. Find details on this milestone for Celldex & those living with CSU/CIndU: https://t.co/CCs2bAwx97